REPORT ID 4545

EMEA (Europe, Middle East and Africa) Opioid Antagonist Drug Market Report 2017

Publish Date
18-Dec-17
Pages
101
Format
Electronic (PDF)

In this report, the EMEA Opioid Antagonist Drug market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Opioid Antagonist Drug for these regions, from 2012 to 2022 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Opioid Antagonist Drug market competition by top manufacturers/players, with Opioid Antagonist Drug sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Pfizer
    Conatus Pharmaceuticals
    Novartis
    Intercept Pharmaceuticals
    Allergan
    Immuron
    Takeda
    Gilead Sciences
    Genfit

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Tablet
    Injection

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    Hospital
    Medical Center

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Opioid Antagonist Drug Market Report 2017
1 Opioid Antagonist Drug Overview
    1.1 Product Overview and Scope of Opioid Antagonist Drug
    1.2 Classification of Opioid Antagonist Drug
        1.2.1 EMEA Opioid Antagonist Drug Market Size (Sales) Comparison by Type (2012-2022)
        1.2.2 EMEA Opioid Antagonist Drug Market Size (Sales) Market Share by Type (Product Category) in 2016
        1.2.3 Tablet
        1.2.4 Injection
    1.3 EMEA Opioid Antagonist Drug Market by Application/End Users
        1.3.1 EMEA Opioid Antagonist Drug Sales (Volume) and Market Share Comparison by Application (2012-2022
        1.3.2 Hospital
        1.3.3 Medical Center
    1.4 EMEA Opioid Antagonist Drug Market by Region
        1.4.1 EMEA Opioid Antagonist Drug Market Size (Value) Comparison by Region (2012-2022)
        1.4.2 Europe Status and Prospect (2012-2022)
        1.4.3 Middle East Status and Prospect (2012-2022)
        1.4.4 Africa Status and Prospect (2012-2022)
    1.5 EMEA Market Size (Value and Volume) of Opioid Antagonist Drug (2012-2022)
        1.5.1 EMEA Opioid Antagonist Drug Sales and Growth Rate (2012-2022)
        1.5.2 EMEA Opioid Antagonist Drug Revenue and Growth Rate (2012-2022)

2 EMEA Opioid Antagonist Drug Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Opioid Antagonist Drug Market Competition by Players/Manufacturers
        2.1.1 EMEA Opioid Antagonist Drug Sales Volume and Market Share of Major Players (2012-2017)
        2.1.2 EMEA Opioid Antagonist Drug Revenue and Share by Players (2012-2017)
        2.1.3 EMEA Opioid Antagonist Drug Sale Price by Players (2012-2017)
    2.2 EMEA Opioid Antagonist Drug (Volume and Value) by Type/Product Category
        2.2.1 EMEA Opioid Antagonist Drug Sales and Market Share by Type (2012-2017)
        2.2.2 EMEA Opioid Antagonist Drug Revenue and Market Share by Type (2012-2017)
        2.2.3 EMEA Opioid Antagonist Drug Sale Price by Type (2012-2017)
    2.3 EMEA Opioid Antagonist Drug (Volume) by Application
    2.4 EMEA Opioid Antagonist Drug (Volume and Value) by Region
        2.4.1 EMEA Opioid Antagonist Drug Sales and Market Share by Region (2012-2017)
        2.4.2 EMEA Opioid Antagonist Drug Revenue and Market Share by Region (2012-2017)
        2.4.3 EMEA Opioid Antagonist Drug Sales Price by Region (2012-2017)

3 Europe Opioid Antagonist Drug (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Opioid Antagonist Drug Sales and Value (2012-2017)
        3.1.1 Europe Opioid Antagonist Drug Sales Volume and Growth Rate (2012-2017)
        3.1.2 Europe Opioid Antagonist Drug Revenue and Growth Rate (2012-2017)
    3.2 Europe Opioid Antagonist Drug Sales and Market Share by Type
    3.3 Europe Opioid Antagonist Drug Sales and Market Share by Application
    3.4 Europe Opioid Antagonist Drug Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Opioid Antagonist Drug Sales Volume by Countries (2012-2017)
        3.4.2 Europe Opioid Antagonist Drug Revenue by Countries (2012-2017)
        3.4.3 Germany Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        3.4.4 France Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        3.4.5 UK Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        3.4.6 Russia Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        3.4.7 Italy Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        3.4.8 Benelux Opioid Antagonist Drug Sales and Growth Rate (2012-2017)

4 Middle East Opioid Antagonist Drug (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Opioid Antagonist Drug Sales and Value (2012-2017)
        4.1.1 Middle East Opioid Antagonist Drug Sales Volume and Growth Rate (2012-2017)
        4.1.2 Middle East Opioid Antagonist Drug Revenue and Growth Rate (2012-2017)
    4.2 Middle East Opioid Antagonist Drug Sales and Market Share by Type
    4.3 Middle East Opioid Antagonist Drug Sales and Market Share by Application
    4.4 Middle East Opioid Antagonist Drug Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Opioid Antagonist Drug Sales Volume by Countries (2012-2017)
        4.4.2 Middle East Opioid Antagonist Drug Revenue by Countries (2012-2017)
        4.4.3 Saudi Arabia Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        4.4.4 Israel Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        4.4.5 UAE Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        4.4.6 Iran Opioid Antagonist Drug Sales and Growth Rate (2012-2017)

5 Africa Opioid Antagonist Drug (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Opioid Antagonist Drug Sales and Value (2012-2017)
        5.1.1 Africa Opioid Antagonist Drug Sales Volume and Growth Rate (2012-2017)
        5.1.2 Africa Opioid Antagonist Drug Revenue and Growth Rate (2012-2017)
    5.2 Africa Opioid Antagonist Drug Sales and Market Share by Type
    5.3 Africa Opioid Antagonist Drug Sales and Market Share by Application
    5.4 Africa Opioid Antagonist Drug Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Opioid Antagonist Drug Sales Volume by Countries (2012-2017)
        5.4.2 Africa Opioid Antagonist Drug Revenue by Countries (2012-2017)
        5.4.3 South Africa Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        5.4.4 Nigeria Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        5.4.5 Egypt Opioid Antagonist Drug Sales and Growth Rate (2012-2017)
        5.4.6 Algeria Opioid Antagonist Drug Sales and Growth Rate (2012-2017)

6 EMEA Opioid Antagonist Drug Manufacturers/Players Profiles and Sales Data
    6.1 Pfizer
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Pfizer Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.1.4 Main Business/Business Overview
    6.2 Conatus Pharmaceuticals
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Conatus Pharmaceuticals Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.2.4 Main Business/Business Overview
    6.3 Novartis
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Novartis Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.3.4 Main Business/Business Overview
    6.4 Intercept Pharmaceuticals
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Intercept Pharmaceuticals Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.4.4 Main Business/Business Overview
    6.5 Allergan
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Allergan Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.5.4 Main Business/Business Overview
    6.6 Immuron
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Immuron Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.6.4 Main Business/Business Overview
    6.7 Takeda
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Takeda Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.7.4 Main Business/Business Overview
    6.8 Gilead Sciences
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Gilead Sciences Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.8.4 Main Business/Business Overview
    6.9 Genfit
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Opioid Antagonist Drug Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Genfit Opioid Antagonist Drug Sales, Revenue, Price and Gross Margin (2012-2017)
        6.9.4 Main Business/Business Overview

7 Opioid Antagonist Drug Manufacturing Cost Analysis
    7.1 Opioid Antagonist Drug Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Opioid Antagonist Drug

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Opioid Antagonist Drug Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Opioid Antagonist Drug Major Manufacturers in 2016
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Opioid Antagonist Drug Market Forecast (2017-2022)
    11.1 EMEA Opioid Antagonist Drug Sales, Revenue and Price Forecast (2017-2022)
        11.1.1 EMEA Opioid Antagonist Drug Sales and Growth Rate Forecast (2017-2022)
        11.1.2 EMEA Opioid Antagonist Drug Revenue and Growth Rate Forecast (2017-2022)
        11.1.3 EMEA Opioid Antagonist Drug Price and Trend Forecast (2017-2022)
    11.2 EMEA Opioid Antagonist Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.3 Europe Opioid Antagonist Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.4 Middle Eastt Opioid Antagonist Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.5 Africa Opioid Antagonist Drug Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
    11.6 EMEA Opioid Antagonist Drug Sales Forecast by Type (2017-2022)
    11.7 EMEA Opioid Antagonist Drug Sales Forecast by Application (2017-2022)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer